Pay in 4 interest-free payments of $6.26 Learn more
Ships within 48 hours · Estimated delivery Aug 25 - Aug 30
Final overall survival and safety analysis of OCEANS, a phase 3 trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent ovarian cancer
Serini, G., Napione, L., Arese, M
Spiser opmrksomt: Mindre, afbalancerede mltider understtter medicinens effektivitet
If you believe you are suffering vision loss from the use of GLP-1s, let us review your case to determine if compensation may be available to you
This convergence is not coincidental
US$ 24.56
US$ 26.56
US$ 24.08
US$ 22.19
US$ 25.55
US$ 20.46
